Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes


A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up




To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes

Study Status: Completed


Condition Intervention Phase
Diabetes, Type I Drug: Technosphere Insulin
Drug: Active comparator
Phase 3

Verified by Mannkind Corporation October, 2009

Sponsored by: Mannkind Corporation
Information provided by: Mannkind Corporation identifier: NCT00308308

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site